1. What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

2. Treatment Options for EGFR Mutation-Positive NSCLC

3. Frontline Metastatic Treatment Options in EGFRm NSCLC

4. TKI + VEGF Inhibition RELAY Trial: Erlotinib +/- Ramucirumab

5. TKI + VEGF Inhibition RELAY Trial - Results

6. Will This Strategy Apply to Osimertinib? Osimertinib + VEGF inhibition

7. TKI + Chemotherapy Gefitinib vs Gefitinib + Chemotherapy

8. TKI + Chemotherapy Results

9. Will This Strategy Apply to Osimertinib? Osimertinib + Chemotherapy

10. Will This Strategy Apply to Osimertinib
Will This Strategy Apply to Osimertinib? Osimertinib + Chemotherapy (cont)

11. Mechanism of Resistance to EGFR TKI MET Amplification

12. Subsequent Line Metastatic Treatment Options in EGFRm NSCLC

13. EGFR/cMET Inhibition Bispecific Antibody: JNJ-372

14. Targeting HER3 ADC: U3-1402

15. Treating Patients With Exon 20 Insertions EGFR/HER2 inhibition: TAK 788

16. Leptomeningeal Disease

17. Diagnostics and Real World Experience

18. 2L Therapy in Patients With EGFRm NSCLC

19. Chemo IO Combinations Keynote 189: PD-(L)1 Inhibitor and Osimertinib

20. Immunotherapy in ≥2L EGFRm NSCLC

21. IMpower150 Atezolizumab + Bevacizumab and Chemotherapy

22. Earlier Treatment Options in EGFRm NSCLC

23. EGFR TKIs as Adjuvant Therapy

24. Does a Longer Duration of Therapy Provide Greater Benefits?

25. Upcoming Trials to Watch

26. Complementary Therapy

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)